CSPC Pharmaceutical Group Limited (CSPCY)
USD 2.94
(13.08%)
USD 2.94
(13.08%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -11.3 Billion CNY | -16.4% |
| 2022 | -9.71 Billion CNY | -5.72% |
| 2021 | -9.18 Billion CNY | -32.36% |
| 2020 | -6.94 Billion CNY | -76.63% |
| 2019 | -3.93 Billion CNY | 9.16% |
| 2018 | -4.32 Billion HKD | 1.14% |
| 2017 | -4.37 Billion HKD | -51.12% |
| 2016 | -2.89 Billion HKD | -50.42% |
| 2015 | -1.92 Billion HKD | -63.99% |
| 2014 | -1.17 Billion HKD | -26.52% |
| 2013 | -928.11 Million HKD | 20.5% |
| 2012 | -1.16 Billion HKD | -100.09% |
| 2011 | -583.5 Million HKD | 23.03% |
| 2010 | -758.08 Million HKD | 40.34% |
| 2009 | -1.27 Billion HKD | -28.72% |
| 2008 | -987.1 Million HKD | -3926.05% |
| 2007 | -24.51 Million HKD | 93.69% |
| 2006 | -388.45 Million HKD | 21.06% |
| 2005 | -492.05 Million HKD | 7.88% |
| 2004 | -534.13 Million HKD | -5.87% |
| 2003 | -504.53 Million HKD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 FY | -11.3 Billion CNY | -16.4% |
| 2023 Q1 | 16.64 Billion CNY | 271.37% |
| 2023 Q2 | -10.05 Billion CNY | -160.36% |
| 2023 Q3 | 13.67 Billion CNY | 236.07% |
| 2023 Q4 | -11.3 Billion CNY | -182.69% |
| 2022 Q2 | -8.38 Billion CNY | 0.0% |
| 2022 Q4 | -9.71 Billion CNY | 0.0% |
| 2022 FY | -9.71 Billion CNY | -5.72% |
| 2021 Q4 | -9.18 Billion CNY | 0.0% |
| 2021 FY | -9.18 Billion CNY | -32.36% |
| 2021 Q2 | -7.92 Billion CNY | 0.0% |
| 2020 FY | -6.94 Billion CNY | -76.63% |
| 2020 Q2 | -5.65 Billion CNY | 0.0% |
| 2020 Q4 | -6.94 Billion CNY | 0.0% |
| 2019 Q2 | -3.76 Billion CNY | 0.0% |
| 2019 FY | -3.93 Billion CNY | 9.16% |
| 2019 Q4 | -3.93 Billion CNY | 0.0% |
| 2018 Q2 | -3.71 Billion HKD | 0.0% |
| 2018 FY | -4.32 Billion HKD | 1.14% |
| 2018 Q4 | -4.32 Billion HKD | 0.0% |
| 2017 Q4 | -4.37 Billion HKD | 0.0% |
| 2017 Q2 | -2.7 Billion HKD | 0.0% |
| 2017 FY | -4.37 Billion HKD | -51.12% |
| 2016 FY | -2.89 Billion HKD | -50.42% |
| 2016 Q2 | -1.85 Billion HKD | 0.0% |
| 2016 Q4 | -2.89 Billion HKD | 0.0% |
| 2015 Q4 | -1.92 Billion HKD | 0.0% |
| 2015 Q2 | -1.5 Billion HKD | 0.0% |
| 2015 FY | -1.92 Billion HKD | -63.99% |
| 2014 FY | -1.17 Billion HKD | -26.52% |
| 2014 Q4 | -1.17 Billion HKD | 0.0% |
| 2014 Q2 | -801.67 Million HKD | 0.0% |
| 2013 Q2 | -758.15 Million HKD | 0.0% |
| 2013 Q4 | -928.11 Million HKD | 0.0% |
| 2013 FY | -928.11 Million HKD | 20.5% |
| 2012 FY | -1.16 Billion HKD | -100.09% |
| 2012 Q4 | -1.16 Billion HKD | 0.0% |
| 2012 Q2 | -789.09 Million HKD | 0.0% |
| 2011 FY | -583.5 Million HKD | 23.03% |
| 2011 Q2 | -620.89 Million HKD | 0.0% |
| 2011 Q4 | -583.5 Million HKD | 0.0% |
| 2010 Q4 | -758.08 Million HKD | 0.0% |
| 2010 FY | -758.08 Million HKD | 40.34% |
| 2010 Q2 | -1.14 Billion HKD | 0.0% |
| 2009 Q4 | -1.27 Billion HKD | 0.0% |
| 2009 FY | -1.27 Billion HKD | -28.72% |
| 2008 FY | -987.1 Million HKD | -3926.05% |
| 2007 FY | -24.51 Million HKD | 93.69% |
| 2006 FY | -388.45 Million HKD | 21.06% |
| 2005 FY | -492.05 Million HKD | 7.88% |
| 2004 FY | -534.13 Million HKD | -5.87% |
| 2003 FY | -504.53 Million HKD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.74 Billion USD | 149.707% |
| Bristol-Myers Squibb Company PFD CONV 2 | 30 Billion USD | 137.694% |
| CSPC Pharmaceutical Group Limited | -1.59 Billion USD | -609.412% |
| Clarus Therapeutics Holdings, Inc. | 15.85 Million USD | 71427.879% |
| Novartis AG | 12.95 Billion USD | 187.289% |
| PT Kalbe Farma Tbk. | -169.7 Million USD | -6563.652% |